Form 4: Unity Biotechnology Executive Alexander Nguyen Reports Stock and Option Awards

Alexander Hieu Nguyen, Chief Legal Officer of Unity Biotechnology, reports the acquisition of restricted stock units and stock options.

Summary

• On March 26, 2024, Alexander Hieu Nguyen, Chief Legal Officer of Unity Biotechnology, reported the acquisition of 20,000 restricted stock units (RSUs) and options to purchase 30,000 shares of common stock.
• The RSUs vest quarterly, starting March 26, 2025, over a three-year period.
• The stock options also vest, with one-fourth vesting on March 26, 2025, and the remainder vesting in equal monthly installments over the following three years, contingent upon continued service.
• The exercise price of the stock options is $1.62.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock and option grants. It indicates confidence in the company's future from the executive, but it's a standard practice.

Positives

• The vesting schedules for both the RSUs and stock options are designed to incentivize continued service and commitment from the Chief Legal Officer.

Future Outlook

The vesting schedules suggest a long-term commitment from the executive, aligning their interests with the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the actions of company executives and other insiders.

Stakeholder Impact

• The vesting schedules for the RSUs and stock options are designed to incentivize continued service and commitment from the Chief Legal Officer, which could benefit shareholders.

Key Dates